Bicycle Therapeutics creates fully synthetic, bi‑cyclic peptide molecules that combine the high affinity of biologics with drug‑like pharmacokinetics, enabling precise targeting of protein‑protein interactions that are difficult for traditional small molecules or antibodies. Their platform delivers rapid tissue penetration, renal clearance, and flexible conjugation to payloads, supporting targeted drug conjugates and immune agonists for solid‑tumor oncology and a range of non‑oncology indications. The company partners with pharma, biotech, and academic groups to develop novel therapeutics for high‑unmet‑need disease targets.

Cambridge GaN Devices develops enhancement-mode GaN transistors that operate with standard silicon gate drivers, eliminating the need for costly external driving interfaces. Their technology addresses the inefficiencies of traditional silicon devices by enabling higher switching frequencies and reducing energy losses by up to 50%, resulting in smaller and more efficient consumer electronics.

Carrick Therapeutics develops targeted cancer therapies that combine CDK12/13 inhibitors with existing oncology drugs to treat aggressive forms of breast, prostate, and ovarian cancers. Their approach addresses the challenge of treatment resistance in advanced cancer patients, aiming to improve clinical outcomes through innovative combination therapies.

CMR Surgical develops the Versius Surgical System, a modular robotic-assisted device designed for minimal access cholecystectomy, utilizing a biomimetic design that mimics the human arm for enhanced precision and control. This technology addresses the limitations of traditional laparoscopic surgery by providing surgeons with improved dexterity, a 710° range of motion, and 3D HD visualization in compact operating room environments.

Complement Therapeutics develops novel therapies that modulate the complement system to address unmet needs in complement‑mediated diseases, most notably geographic atrophy in age‑related macular degeneration. Its pipeline includes an AAV‑based gene therapy (CTx001) for retinal complement dysregulation and protein‑based candidates for systemic conditions, supported by a mass‑spectrometry platform that quantifies multiple complement proteins from a single blood sample for patient stratification and trial monitoring.

Cytora is a risk digitization platform that utilizes large language models to streamline the intake and processing of commercial insurance risks, including new business, claims, and renewals. By automating workflows and integrating data sources, the platform enhances underwriting efficiency, resulting in over 100% productivity improvements for insurers.

DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.

Epitopea develops off-the-shelf RNA immunotherapies that target aberrantly expressed tumor-specific antigens (aeTSAs) identified through its proprietary CryptoMap™ platform. This approach aims to enhance cancer treatment efficacy by providing durable benefits while minimizing side effects for patients with difficult-to-treat cancers.

Develops a tunable duplexer that integrates power amplifiers, low noise amplifiers, and couplers into a single module, using self-interference cancellation techniques to dynamically adapt to multiple frequency bands. This reduces the component count in mobile radio front-end designs, minimizing PCB space, lowering manufacturing costs, and supporting the growing demand for higher data rates and more spectrum in devices like smartphones and wearables.

Gyroscope simplifies optimal liquidity provision in DeFi through its protocol focused on efficient swap yields. It offers users access to concentrated yields in volatile pairs and lower-risk pools for stable assets using asymmetric liquidity. The platform features GYD, a superliquid stablecoin designed to reduce liquidity fragmentation and facilitate on-demand minting and redemption.

Icon provides an all-in-one communication and engagement software designed specifically for organizations that support seniors, utilizing advanced messaging and engagement tools to enhance interactions between older adults and care providers. The platform addresses the challenge of ensuring effective communication and engagement, improving the overall experience for both seniors and their caregivers.

Imagen is an AI-powered photo editing application that integrates with Adobe Lightroom, providing personalized editing by learning individual photographers' styles and applying specific adjustments to each image in under 0.5 seconds. The platform also features AI-driven culling to efficiently select the best photos and offers secure cloud storage for seamless project management.

Microbiotica develops defined live biotherapeutic products that target specific gut bacteria to improve outcomes in inflammatory bowel disease and cancer immunotherapy. Using a clinic‑led discovery platform, the company identifies microbes linked to patient responses and creates precision microbiome medicines with known mechanisms of action, intended for use alongside standard therapies.

MORPHOGEN-IX Limited is a drug discovery company focused on developing bone morphogenetic proteins to enhance tissue regeneration and repair. By targeting the limitations of current regenerative therapies, the company aims to improve patient outcomes in orthopedic and reconstructive medicine.

Mos provides a financial platform for students that combines scholarship matching from a $160 billion database with personalized financial aid advisory services. This solution addresses the challenge of securing funding for education by simplifying the scholarship application process and enhancing access to financial resources.

Niva provides an AI-driven platform for automating Know Your Business (KYB) processes, enabling rapid and secure verification of business identities through real-time data validation and document analysis. By reducing application processing times to under 10 minutes, Niva enhances compliance and minimizes fraud risk, facilitating smoother onboarding for businesses globally.

Nuclera's eProtein Discovery system utilizes cell-free protein synthesis and digital microfluidics to automate the screening, expression, and purification of proteins, delivering active protein samples in under 48 hours. This technology enables researchers to rapidly access and prototype target proteins, significantly accelerating drug discovery workflows.

ON is an AI chat platform designed for enterprise use, integrating with e-commerce systems like Shopify to enhance customer interactions by providing real-time access to product and order information. This technology addresses the high volume of customer service inquiries, improving site conversions and customer satisfaction while reducing the workload for support agents.

Develops veterinary therapeutics, diagnostics, and vaccines for pets, livestock, and equine, leveraging proprietary research and manufacturing processes to address animal health challenges. Its solutions improve disease prevention, detection, and treatment, supporting healthier animals and more productive agricultural systems.

Pretzel Therapeutics develops therapies targeting mitochondrial dysfunction by utilizing advanced mitochondrial biology techniques. This approach addresses over 50 diseases linked to genetic mitochondrial disorders, affecting 1 in 5,000 individuals.

Riverlane is developing the Deltaflow Quantum Error Correction Stack, which provides real-time error decoding and logical orchestration to reduce logical error rates in quantum computing. This technology addresses the high error rates in current quantum systems, enabling them to perform reliable operations at scale and unlock practical applications beyond classical supercomputers.

Salience Labs develops silicon photonic switch chips designed to address fundamental networking bottlenecks within AI infrastructure. These switches enable high-bandwidth, low-latency, all-optical connectivity between compute nodes, removing data movement limitations. The technology facilitates faster AI model performance while reducing power consumption and operational costs.

Secondmind provides a cloud-native optimization engine that utilizes Active Learning to enhance the design and calibration processes for automotive engineers. This technology reduces design simulation time and the number of iterations needed, enabling faster development of energy-efficient vehicles while minimizing reliance on costly prototypes.

Seldon is a machine learning deployment platform that enables organizations to deploy and manage models at scale, reducing deployment time from months to minutes. By providing production-ready inference servers and advanced experimentation tools, Seldon enhances operational efficiency and reduces infrastructure costs, delivering an average productivity gain of 85%.